Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A ganglioneuroblastoma characterized by the presence of neuroblastic cells in a Schwannian stroma, and the formation of hemorrhagic neuroblastic nodules.
Biomarker and diagnostic research for nodular ganglioneuroblastoma has been reported in the published literature.
4 clinical trials registered, 2 recruiting. Interventions under study include procedural interventions, drug therapy, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for nodular ganglioneuroblastoma. Research spans Diagnostic / Biomarker (33%), Review / Meta-Analysis (33%), and Epidemiology / Natural History (33%).
Rasic P (2026). [PMID: 42233020](https://pubmed.ncbi.nlm.nih.gov/42233020/). *Front Immunol*. [Diagnostic / Biomarker]
Gengler C (2025). [PMID: 40835512](https://pubmed.ncbi.nlm.nih.gov/40835512/). *Annales de pathologie*. [Review / Meta-Analysis]
Burnand KM (2025). [PMID: 39582110](https://pubmed.ncbi.nlm.nih.gov/39582110/). *Pediatric blood & cancer*. [Epidemiology / Natural History]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC